Oxford, UK – 10th June 2010. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced that its CytoSure™ Interpret Software can now seamlessly transfer array comparative genomic hybridisation (aCGH) aberration data directly to Cartagenia’s Bench™ constitutional cytogenetics platform. This helps cytogeneticists accurately correlate genotypic findings with known clinical phenotypes. Further details of this new functionality will be presented in two workshops at the European Human Genetics Conference 2010 in Gothenburg, Sweden, 12-15 June. On 12 June, OGT will present “From disease to cytogenetics research – An integrated CNV analysis platform from Oxford Gene Technology” at 12.00 in room H1. Following on from this at 14.00 in room R4, Cartagenia will present “Routine clinical interpretation of copy number variation”.
With the ability to automatically detect CNV aberrations, CytoSure Interpret Software generates reliable and reproducible results, which can be cross referenced with external aberration databases for accurate data interpretation. These results can now be effortlessly transferred to Cartagenia’s Bench platform, allowing additional data management options — including quick and secure data sharing within, and across, various research facilities — and support for genotype-phenotype correlation analysis.
OGT and Cartagenia will be exhibiting at ESHG 2010 on booths B-550 and B-632 respectively. More information on OGT’s CytoSure products can be found at www.ogt.co.uk/cytosure.
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
About Cartagenia
Cartagenia provides patient-based diagnostic knowledge, systems, and services which equip genetics laboratories to perform clinically relevant genetic analyses and obtain results quickly, efficiently, and in a way that enables clinicians to deliver high-standing genetic diagnosis and counselling services.
Bench is Cartagenia’s intelligent database platform and software solution for constitutional cytogenetics enabling rapid clinical interpretation of copy number alterations in patient samples. Cartagenia Bench features support for genotype-phenotype correlation analysis, automatic generation of clinical reports, customisable data entry and data exchange possibilities, semi-automated workflows, management, storage, and organization of assay data, and much more. For a demonstration or trial, please contact info@cartagenia.com.
